JP2018531886A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531886A5
JP2018531886A5 JP2018506211A JP2018506211A JP2018531886A5 JP 2018531886 A5 JP2018531886 A5 JP 2018531886A5 JP 2018506211 A JP2018506211 A JP 2018506211A JP 2018506211 A JP2018506211 A JP 2018506211A JP 2018531886 A5 JP2018531886 A5 JP 2018531886A5
Authority
JP
Japan
Prior art keywords
composition
disease
individual
disorder
caulobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506211A
Other languages
English (en)
Japanese (ja)
Other versions
JP7223989B2 (ja
JP2018531886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/055016 external-priority patent/WO2017033123A1/en
Publication of JP2018531886A publication Critical patent/JP2018531886A/ja
Publication of JP2018531886A5 publication Critical patent/JP2018531886A5/ja
Application granted granted Critical
Publication of JP7223989B2 publication Critical patent/JP7223989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506211A 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法 Active JP7223989B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209693P 2015-08-25 2015-08-25
PCT/IB2016/055016 WO2017033123A1 (en) 2015-08-25 2016-08-22 Immunomodulatory compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018531886A JP2018531886A (ja) 2018-11-01
JP2018531886A5 true JP2018531886A5 (enExample) 2019-09-26
JP7223989B2 JP7223989B2 (ja) 2023-02-17

Family

ID=58100011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506211A Active JP7223989B2 (ja) 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法

Country Status (8)

Country Link
US (3) US11065283B2 (enExample)
EP (2) EP4480544A3 (enExample)
JP (1) JP7223989B2 (enExample)
CN (1) CN107921113A (enExample)
AU (2) AU2016311387B2 (enExample)
CA (1) CA2996383A1 (enExample)
HK (1) HK1248531A1 (enExample)
WO (1) WO2017033123A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214383A1 (en) * 2016-06-10 2017-12-14 The Johns Hopkins University USE OF C1q/TNF-RELATED PROTEIN-1 (CTRP1) TO TREAT FATTY LIVER DISEASE
CN108888762A (zh) * 2018-08-15 2018-11-27 福建傲农生物科技集团股份有限公司 一种含益生菌代谢产物的组合物
CN109966320B (zh) * 2019-04-26 2022-08-05 青岛东海药业有限公司 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
JP2022534783A (ja) * 2019-06-03 2022-08-03 イミュノルクス インターナショナル コーポレーション 疾患を処置するための天然痘ワクチン及び幹細胞
KR102149102B1 (ko) * 2019-07-05 2020-08-27 에스케이바이오랜드 주식회사 피부보습 및 피부재생 기능이 있는 더모바이오틱스 블록 조성물의 제조방법
EP3838269A1 (en) * 2019-12-16 2021-06-23 European Molecular Biology Laboratory Compounds and pharmaceutical compositions for prevention and/or treatment of dysbiosis and antibacterial antidotes for microbiome-protection
CN113440609A (zh) * 2020-03-27 2021-09-28 北京市农林科学院 一种双链rna复合物autp及其在疫苗制备中的应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN113198004B (zh) * 2021-05-19 2022-08-19 天津市宝恒生物科技有限公司 一种修复肠粘膜的凝结芽孢杆菌制剂
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用
US20250230230A1 (en) * 2022-03-24 2025-07-17 The Brigham And Women's Hospital, Inc. Treatment of perivascular fibrosis and other hypertensive diseases and conditions
CN121218993A (zh) * 2023-03-15 2025-12-26 拓比利亚欧斯特有限公司(Acn 652 771 670) 用于治疗、改善或预防病毒感染的制造产品和治疗组合物及其制备和使用方法
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5736371A (en) 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
DK0689454T4 (da) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GEP20022707B (en) 1997-07-18 2002-06-25 Infimed Inc Us Biodegrading Macromers for the Controlled Release of Biologically Active Substances
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
EP1051157B1 (en) 1998-01-30 2002-01-02 Scios Inc. Controlled release delivery of peptide or protein
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2000050073A2 (en) * 1999-02-22 2000-08-31 University Of British Columbia Caulobacter lps immunoadjuvant
DK1163000T3 (da) 1999-03-19 2008-04-28 Glaxosmithkline Biolog Sa Vacciner imod antigener fra bakterier
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
US6458398B1 (en) 1999-10-18 2002-10-01 Eco Pure Food Safety Systems, Inc. Cold water disinfection of foods
EP1255823A4 (en) 2000-01-28 2007-10-31 Azopax Therapeutics Llc PROTEIN POLYMERS WITH SLOW RELEASE
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
EP1377275B1 (en) 2001-03-27 2006-10-25 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CN106102771B (zh) 2014-01-07 2021-06-29 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2018531886A5 (enExample)
Lee et al. Pectic polysaccharides: Targeting gut microbiota in obesity and intestinal health
JP2014534957A5 (enExample)
Yang et al. Fecal microbiota transplantation: Emerging applications in autoimmune diseases
JP2017531002A5 (enExample)
Calabrò et al. Robotic gait rehabilitation and substitution devices in neurological disorders: where are we now?
JP2010535215A5 (enExample)
Schiavi et al. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy
JP2009528991A5 (enExample)
JP2009531292A5 (enExample)
JP2010535218A5 (enExample)
HRP20211050T1 (hr) Pripravci i postupci liječenja degradacije mrežnice
MY186993A (en) Lactobacillus paracasei strain and use thereof
JP2018203742A5 (enExample)
JP2013139462A5 (enExample)
HRP20160843T1 (hr) Bakterija za upotrebu kao probiotik za nutritivne i medicinske primjene
JP2019524784A5 (enExample)
JP2015517489A5 (enExample)
Kowalewicz-Kulbat et al. BCG for the prevention and treatment of allergic asthma
Nuckols et al. Effects of a soft robotic glove using a high repetition protocol in chronic stroke: A pilot study
EP2706067A1 (en) Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders
JP2019531352A5 (enExample)
Guo et al. Engineered probiotics introduced to improve intestinal microecology for the treatment of chronic diseases: present state and perspectives
Amin et al. Probiotics and their applications in functional foods: A health perspective
HRP20200001T1 (hr) Kristalični oblik spoja (s)-3-{4-[5-(2-ciklopentil-6-metoksi-piridin-4-il)-[1,2,4]oksadiazol-3-il]-2-etil-6-metil-fenoksi}-propan-1,2-diol